Li Yinan, Luo Qipeng, Wu Xie, Jia Yuan, Yan Fuxia
Department of Anesthesiology, National Center of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Pediatr. 2020 Jul 24;8:350. doi: 10.3389/fped.2020.00350. eCollection 2020.
The benefit-risk profile of perioperative corticosteroids in pediatric patients undergoing cardiac surgery remains controversial. To investigate the influence of perioperative corticosteroids on the postoperative mortality and clinical outcomes in pediatric patients undergoing cardiac surgery with cardiopulmonary bypass. We conducted a systematic search using MEDLINE, EMBASE, and Cochrane Database through August 31, 2019. We included randomized controlled trials comparing perioperative corticosteroids with other clinical interventions, placebo, or no treatment in children between 0 and 18 years of age undergoing cardiac surgery. The primary outcome of interest was all-cause in-hospital mortality. The secondary outcomes were length of intensive care unit stay (LOIS), duration of mechanical ventilation (DMV), postoperative insulin therapy, postoperative low cardiac output syndrome (LCOS), postoperative infection, maximal temperature ( ) in the first 24 h postoperatively, urine output (UO) in the first 24 h postoperatively, serum lactate at postoperative day (POD) 1, blood glucose at POD 1, vasoactive inotrope score (VIS) at POD 1, and postoperative acute kidney injury (AKI). Study quality was assessed using the Cochrane Risk of Bias Assessment Tool. Our analysis included 17 studies and 848 pediatric patients. The data demonstrated that children receiving corticosteroids showed no significant difference on the all-cause in-hospital mortality with a fixed-effect model (RR = 0.59, 95% CI = 0.28-1.25, = 0.55) compared with controls. For the secondary outcomes, corticosteroids had a statistically significant reduction on the VIS at POD1 (MD = -2.04, 95% CI = -3.96 -0.12, = 0.04), while it might be significantly associated with an increased blood glucose at POD1 (MD = 1.38, 95% CI = 0.68-2.09, = 0.0001) and a 2.69-fold higher risk of postoperative insulin therapy (RR = 2.69, 95% CI = 1.37-5.27, = 0.004). No statistical significance was shown in other secondary outcomes. Perioperative corticosteroids might not significantly improve clinical outcomes identified as mortality, LOIS, DMV, AKI, and LCOS other than VIS at POD1. However, it might increase the blood glucose and episodes of insulin therapy. Perioperative corticosteroids to attenuate the inflammatory response are not supported by available evidence from our study. Further results from ongoing randomized controlled trials with a larger sample size are required.
围手术期使用皮质类固醇激素对接受心脏手术的儿科患者的利弊仍存在争议。为了研究围手术期使用皮质类固醇激素对接受体外循环心脏手术的儿科患者术后死亡率和临床结局的影响,我们于2019年8月31日前使用MEDLINE、EMBASE和Cochrane数据库进行了系统检索。我们纳入了比较围手术期使用皮质类固醇激素与其他临床干预措施、安慰剂或不治疗的随机对照试验,这些试验的对象为0至18岁接受心脏手术的儿童。感兴趣的主要结局是全因住院死亡率。次要结局包括重症监护病房住院时间(LOIS)、机械通气时间(DMV)、术后胰岛素治疗、术后低心排血量综合征(LCOS)、术后感染、术后24小时内最高体温( )、术后24小时内尿量(UO)、术后第1天血清乳酸、术后第1天血糖、术后第1天血管活性药物评分(VIS)以及术后急性肾损伤(AKI)。使用Cochrane偏倚风险评估工具对研究质量进行评估。我们的分析纳入了17项研究和848名儿科患者。数据表明,与对照组相比,接受皮质类固醇激素治疗的儿童在全因住院死亡率方面无显著差异(固定效应模型:RR = 0.59,95%CI = 0.28 - 1.25, = 0.55)。对于次要结局,皮质类固醇激素在术后第1天的VIS方面有统计学显著降低(MD = -2.04,95%CI = -3.96 - 0.12, = 0.04),而它可能与术后第1天血糖升高(MD = 1.38,95%CI = 0.68 - 2.09, = 0.0001)以及术后胰岛素治疗风险高2.69倍显著相关(RR = 2.69,95%CI = 1.37 - 5.27, = 0.004)。其他次要结局未显示统计学显著性。围手术期使用皮质类固醇激素可能不会显著改善除术后第1天VIS之外的死亡率、LOIS、DMV、AKI和LCOS等临床结局。然而,它可能会增加血糖水平和胰岛素治疗的发生率。我们的研究现有证据不支持围手术期使用皮质类固醇激素来减轻炎症反应。需要来自正在进行的更大样本量随机对照试验的进一步结果。